Achilles Therapeutics (Achilles Therapeutics) Pre-Tax Income : $-69.17 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Achilles Therapeutics's pretax income for the three months ended in Dec. 2023 was $-18.13 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-69.17 Mil. Achilles Therapeutics's pretax margin was %.

Achilles Therapeutics Pre-Tax Income Historical Data

The historical data trend for Achilles Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Pre-Tax Income Chart

Achilles Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-13.99

-33.20

-61.06

-71.07

-69.17

Achilles Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial												-24.02	-17.46	-16.88	-16.71	-18.13

Competitive Comparison of Achilles Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Achilles Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achilles Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achilles Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Achilles Therapeutics's Pre-Tax Income falls into.

Achilles Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Achilles Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-75.255	+	6.081	+	0	+	0	+	-1.4210854715202E-14
	=	-69.17

Achilles Therapeutics's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-19.514	+	1.389	+	0	+	0	+	0
	=	-18.13

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.17 Mil.

Achilles Therapeutics (NAS:ACHL) Pre-Tax Income Explanation

Achilles Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-18.125	/	0
	=	%

Achilles Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Achilles Therapeutics (Achilles Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (NAS:ACHL) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

698:Germany

Address

245 Hammersmith Road, London, GBR, W6 8PW

Website

https://www.achillestx.com

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.